U.S. markets closed

Athira Pharma, Inc. (ATHA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.19-0.35 (-3.32%)
At close: 4:00PM EDT

Athira Pharma, Inc.

18706 North Creek Parkway
Suite 104
Bothell, WA 98011-2141
United States
206 221 8115
http://www.athira.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Dr. Leen KawasCEO, Pres & Director706.47kN/A1986
Ms. Glenna K. MilesonCFO & Corp. Sec.417.64kN/A1959
Dr. Hans MoebiusChief Medical Officer425.06kN/A1957
Dr. Mark J. Litton M.B.A., Ph.D., MBAChief Operating OfficerN/AN/A1968
Mr. Robert RenningerDirector of Accounting & ReportingN/AN/AN/A
Ms. Rachel P. LeningtonCTO & Head of Product Devel. StrategyN/AN/AN/A
Mr. Mark F. WorthingtonGen. CounselN/AN/AN/A
Dr. Kevin Church Ph.D.VP of DiscoveryN/AN/A1985
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Corporate Governance

Athira Pharma, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 7. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.